Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 54 Carcinoma, Non-Small-Cell Lung 33 Lung Neoplasms 30 Breast Neoplasms 29 Glioblastoma 23 Multiple Myeloma 21 Glioma 20 Lymphoma 19 Pancreatic Neoplasms 17 Lymphoma, Large B-Cell, Diffuse 17 Carcinoma, Renal Cell 17 Urinary Bladder Neoplasms 16 Brain Neoplasms 14 Sarcoma 13 Squamous Cell Carcinoma of Head and Neck 12 Rectal Neoplasms 11 Neoplasm Metastasis 11 Melanoma 11 Lymphoma, Non-Hodgkin 11 Thyroid Neoplasms 10 Ovarian Neoplasms 10 Oropharyngeal Neoplasms 10 Neuroblastoma 9 Mouth Neoplasms 9 Medulloblastoma 9 Lymphoma, Follicular 9 Ependymoma 9 Colorectal Neoplasms 9 Central Nervous System Neoplasms 9 Astrocytoma 9

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 3 Injections 2 pimonidazole 1 pembrolizumab 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Nitroglycerin 1 Metformin 1 Magnetic Resonance Spectroscopy 1 Hydroxychloroquine 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hypoxia × Magnetic Resonance Spectroscopy × Clear all

NCT02233387 2019-03-08

HX4-cervix

Maastricht Radiation Oncology

Phase 2 Terminated

Hypoxia, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡